<DOC>
	<DOCNO>NCT00928915</DOCNO>
	<brief_summary>Intracerebral haemorrhage ( ICH ) fear complication patient vitamin K antagonist ( VKA ) . VKA relate ICH occur 8-10 time frequently mortality 2 time higher non-anticoagulated patient . Mortality may rise 67 % . The high mortality rate may part due high rate haematoma expansion ( HE ) long period symptom onset . International guideline recommend treatment VKA-ICH prothrombin complex ( PCC ) fresh-frozen plasma ( FFP ) combination Vitamin-K . But recommendation base randomize controlled trial . It know drug low INR , thus assume normalization coagulopathy may lead haemostasis reduction HE . Safety efficacy treatment never study prospective control trial . The investigator ' question : How potent PCC FFP normalization INR ? What safety profile drug ?</brief_summary>
	<brief_title>International Normalized Ratio ( INR ) Normalization Coumadin Associated Intracerebral Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Spontaneous ICH ( intraparenchymal ) , subdural hematoma ( SDH ) diagnose CT scan ≤ 12 hour onset symptom . In case unknown time symptom onset : time last see healthy condition first CCT ≤ 12 hour . Therapy receive vitamin K antagonist ( VKA ) International Normalized Ratio ( INR ) ≥ 2 Signed inform consent form , sign inform consent legal representative , judicial consent case legal representative available time , consent independent physician familiar indication case first three possibility realize . Patients ICH relate vitaminK antagonist therapy Patients secondary ICH related infarction , hemophilia coagulopathy , tumor , hemorrhagic infarction , cerebrovenous thrombosis , aneurysm , arteriovenous malformation ( AVM ) severe trauma Deep Coma ( GCS ≤ 5 ) time admission intubation intubate outside hospital Known previous disability ( mRS &gt; 2 stroke occur ) Acute myocardial ischemia , acute septicemia , acute crush injury , history acute hemorrhagic disseminate intravascular coagulation , acute thrombotic stroke Known history intermittent claudication Known recent thrombotic event &lt; 30 day Acute know congestive heart failure ( NYHA III , IV ) Pulmonary edema Known liver failure ( childpughscore C ) Known alcohol drug abuse Known active malignant disease Known thrombocytopenia ( platelet &lt; 50,000/µL ) , hemorrhagic diathesis ( primary defect coagulation , fibrinolysis , platelet ) History hypersensitivity investigational product drug similar chemical structure excipient present pharmaceutical form investigational product Known allergy heparin history heparin induce thrombocytopenia . Pregnancy lactation Concomitant use antithrombotic ( PTT &gt; 1.5 normal PTT ) , thrombolytic treatment . Use aspirin , clopidogrel dipyridamole combination thereof ( e.g . Aggrenox® ) exclusion criterion . These drug discontinue restart earlier 24 hour normalization INR indicate . Previous participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Intracranial Hemorrhages</keyword>
	<keyword>Vitamin-K antagonist</keyword>
	<keyword>Hemostatic treatment</keyword>
	<keyword>Prothrombin complex</keyword>
	<keyword>Fresh frozen plasma</keyword>
	<keyword>Intracranial Hemorrhages relate vitamin-K antagonist</keyword>
</DOC>